Robins Jason Shand 4

What Happened

• Jason Robins, Interim Chief Financial Officer of Ocular Therapeutix (OCUL), received a grant/award of derivative securities covering 33,000 shares on January 20, 2026. The filing reports a price of $0.00 and total reported value of $0 for the transaction. This is an award (code A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-20; Filing date: 2026-01-22 (appears timely — filed within two business days).
• Reported price per share: $0.00; total reported value: $0.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The shares underlying this award are subject to vesting over four years — vesting 1/48 monthly beginning on the one‑month anniversary of the grant.
• Transaction type: Derivative award (grant/award code A). No immediate sale or exercise reported.

Context

• This is a derivative award subject to vesting; the shares are not immediately free to sell and will vest monthly over four years if Robins continues service. The $0 reporting reflects grant reporting conventions and does not imply marketable proceeds at grant.